Stock Events

Stock Events

Corvus Pharmaceuticals 

$14.73
53
+$0.17+1.17% 20:00 Today
+$0.00+0%20:01After hours

Statistics

Day High
15.04
Day Low
14.37
52W High
26.95
52W Low
5.28
Volume
692,629
Avg. Volume
1,162,019
Mkt Cap
1.24B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.6
-0.43
-0.27
-0.1
Expected EPS
-0.192125
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-15.28MNet Income

Analyst Ratings

36.50Average Price Target
The highest estimate is 40.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRVS. It's not an investment recommendation.
AMD
12
AMD
Palantir Technologies
11
PLTR
Tesla
10
TSLA
SoFi Technologies
9
SOFI

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol Myers Squibb competes in the oncology segment, developing treatments that overlap with Corvus Pharmaceuticals' focus on cancer immunotherapy.
Merck
MRK
Mkt Cap376.37B
Merck is a leading pharmaceutical company with a strong presence in cancer treatment, directly competing with Corvus in the immunotherapy space.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences has a significant focus on oncology and immuno-oncology, areas where Corvus Pharmaceuticals is actively developing therapies.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca operates in various therapeutic areas, including cancer, where its development of immunotherapies competes with Corvus' pipeline.
Pfizer
PFE
Mkt Cap159.99B
Pfizer has a broad portfolio that includes oncology, competing with Corvus Pharmaceuticals in the development of cancer treatments.
Novartis
NVS
Mkt Cap301.95B
Novartis is a global healthcare company with a strong emphasis on research and development in oncology, making it a direct competitor to Corvus.
Roche
RHHBY
Mkt Cap334.28B
Roche, through its Genentech division, is a leader in biotechnology focusing on oncology, which competes with Corvus Pharmaceuticals' focus areas.
AMGEN
AMGN
Mkt Cap237.52B
Amgen focuses on human therapeutics, including oncology and hematology, areas where Corvus is seeking to make advancements.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals is involved in the discovery and development of pharmaceutical products for the treatment of serious medical conditions, including cancer, competing with Corvus.
Incyte
INCY
Mkt Cap25.91B
Incyte Corporation specializes in oncology products, directly competing with Corvus Pharmaceuticals in the development of cancer therapies.

About

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Show more...
CEO
Richard A. Miller
Employees
37
Country
United States
ISIN
US2210151005
WKN
000A2AFXS

Listings

STU
DE
C17.STU
F
DE
C17.F
MU
DE
C17.MU
XNAS
US
CRVS

0 Comments

Share your thoughts

FAQ

What is Corvus Pharmaceuticals stock price today?▼
The current price of CRVS is $14.73 USD — it has increased by +1.17% in the past 24 hours. Watch Corvus Pharmaceuticals stock price performance more closely on the chart.
What is Corvus Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Corvus Pharmaceuticals stocks are traded under the ticker CRVS.
Is Corvus Pharmaceuticals stock price growing?▼
CRVS stock has fallen by -4.35% compared to the previous week, the month change is a +12.7% rise, over the last year Corvus Pharmaceuticals has showed a +165.88% increase.
What is Corvus Pharmaceuticals market cap?▼
Today Corvus Pharmaceuticals has the market capitalization of 1.24B
When is the next Corvus Pharmaceuticals earnings date?▼
Corvus Pharmaceuticals is going to release the next earnings report on October 29, 2026.
What were Corvus Pharmaceuticals earnings last quarter?▼
CRVS earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.16 USD resulting in a -19.4% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Corvus Pharmaceuticals revenue for the last year?▼
Corvus Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Corvus Pharmaceuticals net income for the last year?▼
CRVS net income for the last year is -15.28M USD.
How many employees does Corvus Pharmaceuticals have?▼
As of August 26, 2026, the company has 37 employees.
In which sector is Corvus Pharmaceuticals located?▼
Corvus Pharmaceuticals operates in the Health & Wellness sector.
When did Corvus Pharmaceuticals complete a stock split?▼
Corvus Pharmaceuticals has not had any recent stock splits.
Where is Corvus Pharmaceuticals headquartered?▼
Corvus Pharmaceuticals is headquartered in SOUTH SAN FRANCISCO, United States.